Vizit now indexes biomarkers! Biomarkers are widely employed as biochemical indicators of health and disease states and processes. Their usage spans a wide range of applications including disease prevention, monitoring and assessing the progress of a therapeutic regimen and the appearance of adverse drug reactions and drug interactions. In order to monitor physiological and disease … Read More
Year: 2017
Biovista Vizit tutorial: Quickly explore a disease area
The following short tutorial demonstrates basic usage of Biovista Vizit in a biomedical setting. The tutorial shows how can a biomedical researcher (and/or an MD) quickly get an overview of genes and diseases related to Rheumatoid Arthritis, a common auto-immune disease. 1) Go to https://www.biovista.com/vizit/. Click on the red Start Searching button. 2) From the … Read More
Sarah Bush Lincoln to Use Biovista’s Project Prodigy Artificial Intelligence Engine to Identify and Validate New Therapeutic Options for Further Research
Charlottesville, VA (PRWEB) January 19, 2017 Sarah Bush Lincoln (SBL), a hospital and health care organization that is home to more than 300,000 provider office visits per year, and Biovista announced today that they will be working together to validate novel therapeutic options generated in the real-world practice of a hospital and health center, using … Read More
Customer experience in the life science reagent market: the role of content
Customer experience is emerging as a valuable and defensible differentiator for vendors in the life science reagent market. In the past, product quality and price were the two criteria that strongly determined purchase decisions. But this is no longer the case. Many vendors are already competing on price and at the same time reacting to the increasing pressure … Read More
Biovista announces strong preclinical results for two drugs targeting Niemann-Pick Disease Type A
CHARLOTTESVILLE, Va. – Jan. 12, 2017 – Biovista Inc. today announced that two drugs targeting Niemann-Pick Disease Type A (NPA), have shown strong positive results in the Acid Sphingomyelinase ASM knock-out (ASMKO) mouse model. Both repositioning candidates (BVA-901A and BVA-901B) tested by the laboratory of Dr. M.D. Ledesma at the Madrid Center for Molecular Biology … Read More